- Home
- XENE vs GBDC Comparison
XENE vs GBDC Comparison
Compare XENE & GBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XENE | GBDC |
|---|---|---|
| Founded | 1996 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.6B |
| IPO Year | 2014 | 2010 |
Fundamental Metrics
Financial Performance| Metric | XENE | GBDC |
|---|---|---|
| Price | $42.28 | $13.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | ★ $54.09 | $14.83 |
| AVG Volume (30 Days) | 1.1M | ★ 1.9M |
| Earning Date | 02-26-2026 | 02-04-2026 |
| Dividend Yield | N/A | ★ 11.50% |
| EPS Growth | N/A | ★ 4.09 |
| EPS | N/A | ★ 1.42 |
| Revenue | $7,500,000.00 | ★ $870,777,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.58 |
| Revenue Growth | N/A | ★ 20.16 |
| 52 Week Low | $26.74 | $12.68 |
| 52 Week High | $46.60 | $16.01 |
Technical Indicators
Market Signals| Indicator | XENE | GBDC |
|---|---|---|
| Relative Strength Index (RSI) | 50.52 | 47.77 |
| Support Level | $40.81 | $13.50 |
| Resistance Level | $43.14 | $13.88 |
| Average True Range (ATR) | 1.90 | 0.22 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 66.89 | 39.64 |
Price Performance
Historical ComparisonAbout XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
About GBDC Golub Capital BDC Inc.
Golub Capital BDC Inc. is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in U.S. middle-market companies. It also invests in second-lien and subordinated loans, warrants, and minority equity securities in U.S. middle-market companies. The company generally invests in securities rated below investment grade by independent rating agencies, or those that would be rated below investment grade if evaluated. The company operates in the USA, Canada, and other countries, with the majority of its revenue coming from the USA.